- Home
- SLN vs EAD Comparison
SLN vs EAD Comparison
Compare SLN & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- EAD
- Stock Information
- Founded
- SLN 1994
- EAD 2003
- Country
- SLN United Kingdom
- EAD United States
- Employees
- SLN N/A
- EAD N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- EAD Finance/Investors Services
- Sector
- SLN Health Care
- EAD Finance
- Exchange
- SLN Nasdaq
- EAD Nasdaq
- Market Cap
- SLN 345.3M
- EAD 404.8M
- IPO Year
- SLN N/A
- EAD N/A
- Fundamental
- Price
- SLN $6.24
- EAD $6.88
- Analyst Decision
- SLN Buy
- EAD
- Analyst Count
- SLN 6
- EAD 0
- Target Price
- SLN $39.67
- EAD N/A
- AVG Volume (30 Days)
- SLN 213.8K
- EAD 178.9K
- Earning Date
- SLN 11-07-2025
- EAD 01-01-0001
- Dividend Yield
- SLN N/A
- EAD 8.91%
- EPS Growth
- SLN N/A
- EAD N/A
- EPS
- SLN N/A
- EAD N/A
- Revenue
- SLN $27,169,000.00
- EAD N/A
- Revenue This Year
- SLN N/A
- EAD N/A
- Revenue Next Year
- SLN N/A
- EAD N/A
- P/E Ratio
- SLN N/A
- EAD N/A
- Revenue Growth
- SLN 22.28
- EAD N/A
- 52 Week Low
- SLN $1.97
- EAD $5.69
- 52 Week High
- SLN $18.24
- EAD $6.81
- Technical
- Relative Strength Index (RSI)
- SLN 46.82
- EAD 43.80
- Support Level
- SLN $7.06
- EAD $6.90
- Resistance Level
- SLN $7.39
- EAD $6.97
- Average True Range (ATR)
- SLN 0.58
- EAD 0.05
- MACD
- SLN -0.12
- EAD 0.01
- Stochastic Oscillator
- SLN 21.87
- EAD 60.87
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.